GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general med...
GSK reports mixed findings from ovarian cancer phase III study
GSK's First-Engot-OV44 phase III trial met primary endpoint for ovarian cancer treatments niraparib and dostarlimab, showing progression free survival improvement. However, key secondary endpoint of overall survival did not meet statistical significance. Further analyses ongoing.
GSK Reports Headline Results From FIRST-ENGOT-OV44 Phase III Trial
GSK's FIRST-ENGOT-OV44 phase III trial met primary endpoint of PFS with Zejula and Jemperli in advanced ovarian cancer, showing significant difference with dostarlimab added to standard care. Overall survival did not meet statistical significance.
Headline results from phase III FIRST trial
GSK announced the FIRST trial met its primary endpoint of progression free survival in first-line advanced ovarian cancer, with the addition of Jemperli (dostarlimab) to platinum-based chemotherapy and Zejula (niraparib) maintenance demonstrating a statistically significant effect on PFS.
Phase III SWIFT Trials Show Ultra-Long-Acting Biologic Depemokimab Reduces Severe
Depemokimab, an anti–IL-5 therapy, significantly reduced annual asthma exacerbations in severe eosinophilic asthma patients in SWIFT-1 and SWIFT-2 trials, with an acceptable safety profile. Administered every six months, it showed a binding affinity for IL-5, enabling effective dosing intervals and potentially improving patient quality of life.
Cautious Outlook on GlaxoSmithKline: Sell Rating Due to Pipeline and Financial Challenges
Bank of America Securities analyst Graham Parry maintains a Sell rating on GSK stock, citing challenges in GlaxoSmithKline's early-stage oncology and respiratory R&D, potential revenue declines from HIV drugs, and increased margin pressure. J.P. Morgan also maintains a Sell rating with a £14.40 price target.
FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer
FDA grants breakthrough therapy designation to dostarlimab-gxly (Jemperli) for locally advanced dMMR/MSI-H rectal cancer, based on a 100% clinical complete response rate in a phase 2 study. The treatment showed sustained cCR and a favorable safety profile, with no grade 3 or higher AEs. The AZUR-1 trial continues to evaluate dostarlimab in this patient population.
Myositis Therapeutics Market Report 2024: Comprehensive
The 'Myositis - Pipeline Insight, 2024' report by ResearchAndMarkets.com offers insights into 18+ companies and 20+ pipeline drugs for Myositis, covering drug profiles, therapeutic assessments, and pipeline development activities.
Recent Biologics Deals - Life Sciences, Biotechnology & Nanotechnology
Recent biologics deals include Duality Biologics' exclusive option agreement with GSK for ADC candidate DB-1324, Keros Therapeutics' global license agreement with Takeda for elritercept, Merus' license agreement with Partner Therapeutics for NRG1+ cancer antibody Zeno, and Sanofi's opening of a modular vaccine and biopharmaceutical facility in Singapore.
GSK announces CHMP of the EMA recommended expanding approval of Jemperli
GSK announced CHMP of EMA recommended expanding approval of Jemperli with chemotherapy for first-line treatment of primary advanced or recurrent endometrial cancer in adult patients, including those with mismatch repair proficient/microsatellite stable tumours. Approval decision expected Q1 2025.
© Copyright 2024. All Rights Reserved by MedPath